The next step when antidepressants fail
FDA-approved Clinician-directed
Home-based
The Proliv™Rx System provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment.
It is intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in clinic. It is a prescription-only device.
Where depression care falls apart
After first line of treatments fall short, the gap in next-step care turns early failure into chronic depression
The Pressure Builds Across Every Step Of The Care Pathway:
- Medication cycling continues with low chances of remission.
- Clinic-based neuromodulation is limited by geography, staffing, and long waitlists.
- Escalation takes too long, especially for patients without access to specialists.
- Overhead and clinical burden grow, requiring new rooms, technicians, scheduling capacity, and coordination
- Crisis utilization rises, driving Emergency Room visits and admissions.
Most patients never reach an effective next-step intervention and it is this that drives more than half the cost or economic burden of depression.
A physician-directed next-step therapy, delivered at home
Proliv™Rx is an FDA-approved neuromodulation therapy designed specifically for the gap after first-line depression treatments fall short.
Proliv™Rx is an FDA-approved neuromodulation therapy designed specifically for the gap after first-line depression treatments fall short.
It combines an at-home treatment experience with continuous physician direction and visibility throughout the program.
Adults who haven’t improved on antidepressants complete a guided 8-week treatment at home, while clinicians track symptoms, compliance and progress throughout the program.
- FDA-approved, prescription-directed therapy
- Structured 8-week treatment program with optional prescription extension.
- Home-based delivery with physician oversight
- Continuous adherence and symptom tracking
- No additional clinic equipment, staffing, or geographic limitations
Measurable impact at the next critical step in care
- Depression severity levels:
Very Severe, Severe, Moderate, Mild, No Depression. - After completion of a 16-week therapy program.
After completion of a 16-week therapy program.
Who Proliv™Rx is for
How Proliv™Rx compares
An effective, more scalable path forward once medications fail
Proliv™Rx was well tolerated in clinical studies, with no device-related unanticipated serious adverse events reported.
Observed adverse events were generally mild to moderate in severity and transient in nature.
The most commonly reported adverse events included scalp numbness, localized skin reactions at the electrode sites, and headache.
What leading psychiatrists are saying
Director, Center for Advanced Imaging Research & Brain Stimulation Laboratory, MUSC
